Literature DB >> 11697685

Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma.

S Kuzuhara1.   

Abstract

Psychotic symptoms develop in 20-30% of patients with Parkinson's disease (PD) receiving chronic anti-PD medications, and visual hallucinations with or without delirium and paranoid delusions are the most frequent symptoms. Psychotic symptoms disturb ADL and QOL of PD patients and tax caregivers far more than the motor disabilities do, and good management of drug-induced psychotic symptoms is potentially important. Withdrawal of anti-PD drugs relieves the patients from psychotic side effects, but worsens the parkinsonian motor symptoms. The first step of treatment is to eliminate triggering factors other than anti-PD drugs, such as infections, metabolic disorders, subdural hematoma, and hallucinogenic drugs. The second step is to eliminate anti-PD drugs in the following order; first anticholinergics, amantadine and selegiline, second dopamine agonists, and finally levodopa/carbidopa. Anti-PD medications should be reduced to the point of improving psychotic side effects without drastically worsening parkinsonian motor symptoms. When the above adjustments fail to sufficiently alleviate psychotic side effects, the third step is consideration of antipsychotic drugs although they have potential capacity to antagonize dopamine D2 receptors and worsen parkinsonism. Atypical antipsychotics such as clozapine and olanzapine are recommended, though the former is not available in Japan.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697685     DOI: 10.1007/pl00007823

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Neuropsychiatric phenomena associated with movement disorders.

Authors:  Joshua L Roffman; Todd Eisenberg; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  Delusional Infestation in Parkinson's Disease.

Authors:  Jennie L Davis; Julie A Kurek; Kapil D Sethi; John C Morgan
Journal:  Mov Disord Clin Pract       Date:  2016-03-31

3.  Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease.

Authors:  O Grau-Rivera; E Gelpi; M J Rey; F Valldeoriola; E Tolosa; Y Compta; M J Martí
Journal:  J Neurol       Date:  2013-09-18       Impact factor: 4.849

Review 4.  Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia.

Authors:  Dhiren Singh; Daniel W O'Connor
Journal:  Clin Interv Aging       Date:  2009-09-01       Impact factor: 4.458

Review 5.  Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.

Authors:  Caroline H Williams-Gray; Thomas Foltynie; Simon J G Lewis; Roger A Barker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate.

Authors:  Christopher A Lieu; Kala Venkiteswaran; Timothy P Gilmour; Anand N Rao; Andrew C Petticoffer; Erin V Gilbert; Milind Deogaonkar; Bala V Manyam; Thyagarajan Subramanian
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-10       Impact factor: 2.629

7.  New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.

Authors:  Jennifer G Goldman
Journal:  Parkinsons Dis       Date:  2011-03-02

8.  Bifrontal ECT for drug-induced psychosis in Parkinson's disease.

Authors:  K Muralidharan; R Thimmaiah; V Chakraborty; S Jain
Journal:  Indian J Psychiatry       Date:  2011-04       Impact factor: 1.759

9.  Patient perspectives on Parkinson's disease therapy in Japan and the United States: results of two patient surveys.

Authors:  Nobutaka Hattori; Kenichi Fujimoto; Tomoyoshi Kondo; Miho Murata; Mark Stacy
Journal:  Patient Relat Outcome Meas       Date:  2012-07-11

10.  Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia.

Authors:  Rosa Catalán; Rafael Penadés
Journal:  J Cent Nerv Syst Dis       Date:  2011-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.